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| BACKGROUND
Hemophilia A (HA) is one of the most common severe hereditary coagulation disorders and is caused by factor VIII (FVIII) abnormalities.
The hallmark of severe HA is spontaneous bleeding into joints and muscles that can be painful and destructive if inadequately treated.
Most patients with severe HA require regular replacement therapy, but a small proportion of patients exhibit a mild clinical presentation and need only occasional treatment. 1, 2 The FVIII and Factor
IX Subcommittee of the International Society of Thrombosis and
Hemostasis has recommended that plasma levels be used to classify hemophilia severity into 3 groups: mild, FVIII >5 to 40 IU/dL; moderate, FVIII 1 to 5 IU/dL; and severe, FVIII <1 IU/dL. 3, 4 Management of severe HA includes infusion of FVIII on a regular basis to convert the bleeding pattern from a severe to a moderate phenotype, maintaining FVIII trough levels above 1 IU/dL, 5 and reducing spontaneous bleeds. 6 Accurate measurement of coagulation potential is thus critical to diagnose and manage HA. Clinical laboratories most commonly measure FVIII activity (FVIII:C) by one-stage activated partial thromboplastin time (APTT) clotting assays (OSA). 7 The quality of the deficient plasma, activating reagent, type of standard, and other analytical variables define the lower assay limit. 8 As a result, the lower limit of quantitation for conventional assays is approximately 1.0 IU/dL, 9 although trough levels are titrated to maintain FVIII ≥1 IU/dL. Furthermore, OSAs mainly capture the initial thrombin generation required for clot formation.
Nevertheless, 95% of thrombin generation occurs after initial clot formation. 10 Thus, OSAs do not simulate in vivo hemostasis 11 and may fail to characterize the true severity of the HA phenotype.
Of patients diagnosed with severe HA, about 10% present with a milder phenotype.
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In contrast, global assays such as rotational thromboelastometry (ROTEM), the thrombin generation assay (TGA), and clot waveform analysis reflect a greater range of interactions among procoagulants, anticoagulants, and platelets. Results obtained by thromboelastography are dependent on the activity of the plasma coagulation system, platelet function, and fibrinolysis. TGA reflects the interaction of procoagulants and select anticoagulants and can be performed on both platelet-poor plasma (PPP) and platelet-rich plasma (PRP).
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Clot waveforms are derived from constant light-transmittance measurement taken during routine APTT assays. These sigmoid patterns reflect parameters from the clotting process such as minimum value of first derivative (Min1; coagulation acceleration) and minimum value of second derivative (Min2; coagulation velocity). [13] [14] [15] Many To investigate and understand differences in global and conventional laboratory assays in the diagnosis and management of HA, we measured the coagulation potential of patients with severe, moderate, and mild HA using thromboelastometry, TGA, and clot waveform analysis and compared the parameters to conventional APTT tests and FVIII levels.
| PATIENTS/METHODS

| Patients and controls
Patients who participated in this research had previously identified HA and were registered at the Katharine Dormandy Haemophilia 
Essentials
• Three global assays were used to measure the coagulability of hemophilia A (HA) blood.
• Specific conditions in ROTEM analysis were sensitive for the heterogeneity of coagulation profiles.
• Peak height in thrombin generation assay was most sensitive for severity of HA.
• Clot waveform analysis correlated more strongly with factor VIII levels than did the APTT. 
| FVIII activity measurements
Factor VIII activity was measured using APTT lyophilized reagent 
| Thromboelastometry analysis
Thromboelastometry using ROTEM (Pentapharm GmbH, Munich, Germany) analysis was performed immediately after collection of citrated whole blood (CWB) samples with or without CTI and activated with recombinant TF (Innovin, Dade Behring, Marburg, Germany), using the nonactivated thromboelastometry protocol.
As samples were taken prior to the availability of commercial CTI tubes, CTI was added to tubes before sample collection. All samples taken for ROTEM analysis were rested for 30 minutes (as instructed by the manufacturer) before the test was performed as per protocol. ROTEM in this study was performed as described by Sørensen et al. 30 Based on their methodology, the final TF (Innovin, Dade 
| Thrombin generation assay
Thrombin generation assay was performed by an in-house method based on Hemker et al. . The amount of thrombin generated was calculated according to the method of Hemker and Beguin. 35 Peak height (PH), area under the curve (AUC), and time to PH were calculated. 36 All parameters were normalized against pooled control plasma prepared using the same method as patient PPP samples (controls were run with each test).
| Clot waveform analysis
APTT tests were performed on the MDA coagulometer (Organon Teknika, Cambridge, UK) using MDA Platelin LS and Platelin LS CaCl 2 reagents (Organon Teknika), according to the manufacturer's protocol. Aliquots of patient and control group plasma were stored at −80°C immediately after processing and were thawed before testing. Min1 (coagulation velocity, percent change in transmittance
[T]/s) and Min2 (coagulation acceleration, percent change in T/s 2 )
were observed and analyzed as previously described.
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| Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 (GraphPad Software, La Jolla, CA, USA 
| Thromboelastometry analysis
Thromboelastometry tests were performed in all HA patient groups under 3 different sample and analytic combinations: CWB, CWB+TF, and CWB+CTI+TF for CT, CFT, α°, MaxVel, tMaxVel, and AUCVel.
In all patient and healthy volunteer samples, CWB+TF condition had shorter CT and CFT than CWB or CWB+CTI+TF (Tables 1 and 2 ).
HA patient groups and the control group were significantly different for CT, CFT, α°, MaxVel, and tMaxVel in all 3 test conditions (Tables   1 and 2 ).
For AUCVel, however, the HA patient groups and the control group were significantly different in all conditions except for mild CWB HA samples and moderate and mild CWB+CTI+TF HA samples (Tables 1 and 2 ).
For CWB samples, CT, CFT, α°, and tMaxVel median differences 0.002, respectively) ( Table 2 ). The median tMaxVel difference for moderate HA vs. mild HA was 6.1 minutes (2.9-10.5; P = 0.010). In Figure 1D ).
Across all severities of HA, the sensitivity for MaxVel was the highest in CWB+CTI+TF (92%; 85% in CWB+TF and 90% in CWB).
The specificity was 95% for all test conditions. The positive likelihood ratio, therefore, was highest in CWB+CTI+TF (20.31), followed CWB (18.08) and CWB+TF (16.19) .
To avoid skewed results, the ROC analysis was repeated for the mild HA patient group (n = 16) only compared with the control group (n = 22). This analysis found that tMaxVel in sample condition CWB was the most sensitive parameter (100%) of thromboelastometry (95% specificity, 20.0 likelihood ratio). This is compared to sensitivity, specificity, and likelihood ratio of 71%, 89%, and 6.79 in CWB+TF, and 54%, 95%, and 11.85 in CWB+TF+CTI. The sensitivity and specificity of CWB+TF+CTI MaxVel in mild HA was 85% and 95%, respectively. 
| TGA analysis
HA patient groups had significantly lower PH and AUC, and longer PH than control samples (Table 3, Table S1 ).
In PPP, PHs of severe HA patients were 7% (3%-20%) lower with CTI and 28% (3.3%-34.2%) lower with no CTI than moderate HA patients (P < 0.002 for both). In PPP+CTI samples, median PH was 8% (4%-13%) lower for the severe HA group than severe >1 IU/dL patient group (P = 0.0015) ( Figure 2B ). However, median of PPP for the mild and moderate groups were similar (Figure 2A-D Using the Wilcoxon paired test, PH values for HA patient PPP samples were significantly lower than PRP samples without CTI (P = 0.0004) and with CTI (P = 0.02). No differences were found between the PHs of PPP and PPP+CTI samples (P = 0.14), and PRP and PRP+CTI (P = .73) samples (Figure 2A-D) .
| Clot waveform analysis
Min1 and Min2 were significantly lower in all HA patient groups compared to control samples ( Table 4) .
As with thromboelastometry and TGA analyses, ROC was performed for the mild HA patients group compared to the healthy patient group, resulting in a 93% sensitivity, 96% specificity, and 21.5
likelihood ratio for Min1 and 80% sensitivity, 96% specificity, and Thromboelastometry analysis with CWB and CWB+CTI+TF was the most useful for identifying the heterogeneity of patients' global coagulation profiles.
The tMaxVel of CWB samples distinguished individuals with HA from the healthy population with 100% sensitivity and 94% specificity. However, the CWB test condition does not add discriminatory or diagnostic value to conventional assays. CWB is dominated by contact activation and coagulation through the intrinsic pathway, mimicking the OSAs. Addition of CTI and TF ensures activation through the extrinsic pathway followed by the intrinsic pathway, simulating in vivo coagulation. In CWB+CTI+TF samples, MaxVel differentiated between the severe, moderate, and mild hemophilia populations and strongly correlated with individual FVIII levels. Furthermore, CWB+CTI+TF MaxVel had an 85% sensitivity and 95% specificity for the diagnosis of mild HA.
In CWB+TF samples, however, MaxVel was less sensitive (57%) but specific (95%), indicating that CTI is essential to improve the sensitivity when TF is used to activate coagulation.
The MaxVel was markedly depressed in severe HA, but increased proportionally in patients with moderate and mild hemophilia. The absence of statistical significance between severe and moderate HA may be related to lack of complete washout, or represent underlying variability contributing to fewer bleeding episodes in some severe patients and marked bleeding tendency in some moderate patients.
TF initiation improved the tracing, but dramatically increased variability, particularly in the severe HA group. This variability might be due to clot formation by other components of blood (such as red blood cells, platelets, and white blood cells). It is also possible that thromboelastometry identified changes in FVIII levels at <1.0 IU/ dL in this study. Indeed, the correlation between the MaxVel in CWB+CTI+TF and the level of FVIII was strong and significant, and the linear regression analysis showed a significant coefficient of determination.
Clinical application of the TGA has increased in recent years, but its utility and reliability in various clinical scenarios remains unclear [22] [23] [24] [39] [40] [41] [42] . TGA appears to be a reliable test for excluding individuals with lower than normal coagulation FVIII levels. In this study, the use of CTI to eliminate the interference of contact-activated coagulation improved the accuracy and precision of thrombin generation measures. In particular, PH with PRP+CTI samples achieved 100% sensitivity and a likelihood ratio of 18.0 (PRP: 83% sensitivity, likelihood ratio, 15.0).
Although the results generally confirmed differences between severe, moderate, and mild groups, there were a number of cross- In the present study, the clot waveform parameters, Min1 and Min2, appeared to be reliable predictors of FVIII levels <1.0 IU/dL.
The wide ranges of Min1 (5th-95th percentile = 8%-47%) and Min2
(5th-95th percentile = 5%-48%) suggests that heterogeneity exists 53 and improve clinical outcomes. 54 .
However, the small number of subjects in this study, and other limitations, means that further research with robust clinical end points is required to define the roles of these assays in clinical care.
| CONCLUSION
The sensitivity and specificity of the global assays was method dependent. The use of CTI and low doses of TF enhanced the sensitivity of both TGA and thromboelastometry. TGA of PRP with TF in the presence of CTI was able to discriminate between severe and moderate HA. Similarly, with thromboelastometry, MaxVel in CWB+CTI+TF samples differentiated between the severe, moderate, and mild HA populations and strongly correlated with individual FVIII levels.
Furthermore, clot waveform analysis was more sensitive and correlated better with FVIII level than APTT and could potentially be incorporated into the methodology for factor assay measurement.
Correlation between clinical end points and thrombin generation might also be valuable in the era of non-replacement product therapy.
